Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...The sale of the 36.5 per cent share is part of a realignment taking place in the global consumer healthcare sector, which has also seen Pfizer of the US put its consumer healthcare unit up for sale....
...He has moved to disentangle Novartis from part of the asset swap deal struck four years ago with GSK: a multi-pronged agreement that his predecessor, Joe Jimenez, had identified to the FT in a valedictory...
...Erik Nordkamp, the UK head of Pfizer, says the future of healthcare will involve “a convergence of technologies to come to better solutions”....
...“If companies can get to the market quicker, that’s good for us and the whole system,” said Ian Read, chief executive of Pfizer....
...He has recruited Mike Ball, former chief executive of Hospira, the US drugmaker recently acquired by Pfizer, to replace Jeff George as head of Alcon and set him a target to return the unit to growth by the...
...Pfizer is planning to go further with the likely separation of its “established products” portfolio of older drugs by 2019....
...Roche and Pfizer, two of the world’s biggest drugmakers, have deals with 23andMe to tap its data for use in research....
...Pfizer’s failed $110bn offer for AstraZeneca also showed that mergers among the biggest groups cannot be ruled out altogether....
...But Mr Jimenez insists the new generation of targeted medicines offer better value than the one-size-fits-all drugs of the past....
...But Joe Jimenez, Novartis’s chief executive, says it is also driven by anxiety over new challenges ahead as companies scramble for the best strategic positions in a changing healthcare landscape....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Meanwhile, shares in AstraZeneca jumped almost 5 per cent on Tuesday after it emerged Pfizer had made a tentative $100bn takeover approach that would have resulted in the biggest pharmaceuticals deal on...
...“There are assets embedded in most companies that are worth more to others,” says Joe Jimenez, chief executive of Novartis....
...Joe Jimenez, Novartis’s chief executive, hints at more disposals to come....
...Yet Mr Jimenez and Mr Vasella are among the top 10 best paid – and the only ones from a European company....
...But Joe Jimenez, chief executive, stressed continuity between Mr Vasella and Mr Reinhardt over strategy....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Ian Read, the Scottish-born chief executive of Pfizer of the US, who a year ago caused shock in the UK life-science sector by closing its longstanding research centre at Sandwich in Kent, stresses: “You...
...The move is the latest in a series of cuts by drug companies in the UK, including the decision in January by Pfizer of the US, one of the largest foreign investors in the sector in the country, to close...
...To back his arguments, Mr Jimenez notes “focused diversification” is gaining momentum in the industry, as rivals such as Sanofi, Pfizer and even Merck broaden their activities....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
International Edition